Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative chemoradiation versus upfront surgery for resectable pancreatic head adenocarcinoma
ISRCTN78805636Phase 2Completed
- Sponsor
- Friedrich-Alexander University Erlangen-Nuremberg
- Start
- Jun 2003
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and cisplatin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Friedrich-Alexander University Erlangen-Nuremberg. Primary endpoint: Median survival. Started Jun 2003; status: completed.
02
Drugs
gemcitabinecisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN78805636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78805636.